Ignacio
Matos García
Consultor Médico
University of Chicago
Chicago, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Chicago (1)
2021
-
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
The Lancet Respiratory Medicine, Vol. 9, Núm. 6, pp. 613-621